We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$53.3M
Cap. Flow
+$23M
Cap. Flow %
4.23%
Top 10 Hldgs %
49.87%
Holding
88
New
19
Increased
18
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13M
2
SRRK icon
Scholar Rock
SRRK
+$10.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.4M
4
PCVX icon
Vaxcyte
PCVX
+$9.43M
5
PFE icon
Pfizer
PFE
+$8.03M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$14.9M
2
VRNA
Verona Pharma
VRNA
+$13.9M
3
IRON icon
Disc Medicine
IRON
+$11.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.97M
5
WVE icon
Wave Life Sciences
WVE
+$8.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELUT icon
26
Elutia
ELUT
$40.6M
$5.47M 1.01%
2,761,684
+91,628
+3% +$185K
CGEN icon
27
Compugen
CGEN
$215M
$5.4M 1%
3,033,879
+138,449
+5% +$205K
TELA icon
28
TELA Bio
TELA
$32.1M
$5.39M 0.99%
2,779,795
+8,507
+0.3% +$11.1K
ABEO icon
29
Abeona Therapeutics
ABEO
$338M
$5.21M 0.96%
+917,898
New +$5.22M
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
$5.06M 0.93%
+103,943
New +$2.5M
CLDX icon
31
Celldex Therapeutics
CLDX
$2.76B
$4.04M 0.74%
198,441
-7,521
-4% -$146K
AARD
32
Aardvark Therapeutics
AARD
$145M
$3.88M 0.72%
286,807
+167,311
+140% +$1.72M
MLTX icon
33
MoonLake Immunotherapeutics
MLTX
$1.61B
$3.87M 0.71%
+82,023
New +$3.34M
SNDX icon
34
Syndax Pharmaceuticals
SNDX
$1.72B
$3.77M 0.7%
402,964
-906,260
-69% -$9.97M
GPCR icon
35
Structure Therapeutics
GPCR
$3.37B
$3.64M 0.67%
175,636
-12,433
-7% -$273K
CCOI icon
36
CALL
Cogent Communications
CCOI
$640M
$3.59M 0.66%
+500,000
New +$25.4M
CERS icon
37
Cerus
CERS
$589M
$3.51M 0.65%
2,488,291
+31,754
+1% +$42.3K
ERAS icon
38
Erasca
ERAS
$6.3B
$3.26M 0.6%
2,569,591
-4,798,405
-65% -$6.42M
CMPX icon
39
Compass Therapeutics
CMPX
$362M
$3.25M 0.6%
1,249,781
+374,912
+43% +$773K
SION
40
Sionna Therapeutics
SION
$2.03B
$3.23M 0.6%
186,015
+71,877
+63% +$942K
BNTC icon
41
Benitec Biopharma
BNTC
$412M
$2.96M 0.55%
253,234
+3,234
+1% +$45.2K
TRVI icon
42
Trevi Therapeutics
TRVI
$2.58B
$2.95M 0.54%
539,587
+9,587
+2% +$59.6K
QURE icon
43
uniQure
QURE
$2.46B
$2.82M 0.52%
202,565
-835
-0.4% -$11.2K
HIMS icon
44
PUT
Hims & Hers Health
HIMS
$6.62B
$2.49M 0.46%
+50,000
New +$2.26M
KNSA icon
45
Kiniksa Pharmaceuticals
KNSA
$6.02B
$2.1M 0.39%
75,959
-12,256
-14% -$312K
ORKA
46
Oruka Therapeutics
ORKA
$5.35B
$1.85M 0.34%
+165,389
New +$1.72M
DNTH icon
47
Dianthus Therapeutics
DNTH
$5.59B
$1.78M 0.33%
95,806
-94,528
-50% -$1.77M
TRML
48
DELISTED
Tourmaline Bio
TRML
$1.75M 0.32%
+109,257
New +$1.77M
MLYS icon
49
Mineralys Therapeutics
MLYS
$2.34B
$1.56M 0.29%
115,282
-223,072
-66% -$3.23M
KOD icon
50
Kodiak Sciences
KOD
$2.48B
$1.5M 0.28%
401,540
-40,267
-9% -$143K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Silverarc Capital Management held 88 positions worth $542M, up 11% from $489M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $23M of net new capital in Q2 2025, opening 19 new positions and adding to 18 existing holdings. Its largest new stake was CG Oncology: 541,034 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $14.9M trimmed.

  • Silverarc Capital Management's largest Q2 2025 buy was CG Oncology: 541,034 shares worth $14.1M.
  • Silverarc Capital Management added most to Neurocrine Biosciences in Q2 2025, an estimated $10.4M increase.
  • Silverarc Capital Management's biggest Q2 2025 reduction was Nuvalent, cutting an estimated $14.9M.
  • Silverarc Capital Management fully exited Disc Medicine in Q2 2025, selling an estimated $11.7M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $542M portfolio in Q2 2025.
  • Silverarc Capital Management opened 19 new positions and closed 23 in Q2 2025.
  • Silverarc Capital Management's portfolio value rose 11% quarter-over-quarter to $542M.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.